Consensus Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-30 EDT			5-day change	1st Jan Change
30.91 ^USD	+5.68%		+7.14%	-4.30%

04-30	Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise	MT
04-30	Transcript : Harmony Biosciences Holdings, Inc., Q1 2024 Earnings Call, Apr 30, 2024

Evolution of the average Target Price on Harmony Biosciences Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

aa247ed77775e8d8bd435ef1cd4cfa02.X6mHY1Rrhmhs1yQ-pPF4shg2Ib7VCKi3oxL_gkx14X8.CNnCLwIatF0c7lcJ1JgWn3JRaNSda-379lbNzR8xsxUPzt8qbAzyOQjvTw~b36f18c72db4e66d5ef1b1f58a90cd31

Analyst Recommendations on Harmony Biosciences Holdings, Inc.

Mizuho Securities Cuts Price Target on Harmony Biosciences to $40 From $42, Maintains Buy Rating	02-27	MT
Needham Cuts Price Target on Harmony Biosciences to $50 From $53, Maintains Buy Rating	02-23	MT
Mizuho Boosts PT on Harmony Biosciences to $42 From $33 Ahead of Q4 2023 Earnings Announcement, Maintains Buy Rating	02-15	MT
Goldman Sachs Adjusts Price Target on Harmony Biosciences Holdings to $28 From $25, Maintains Sell Rating	01-09	MT
BofA Securities Downgrades Harmony Biosciences Holdings to Underperform From Neutral	01-02	MT
Mizuho Raises Price Target on Harmony Biosciences to $33 From $28 on 'Continued Commercial Execution', Reiterates Buy Rating	11-06	MT
Raymond James Adjusts Price Target on Harmony Biosciences to $27 From $26, Maintains Outperform Rating	11-01	MT
Mizuho Slashes Price Target on Harmony Biosciences to $28 From $54, Keeps Buy Rating	23-10-19	MT
Needham Cuts Price Target on Harmony Biosciences to $53 From $66, Keeps Buy Rating	23-10-16	MT
Raymond James Adjusts Price Target on Harmony Biosciences to $26 From $58, Keeps Outperform Rating	23-10-16	MT
Goldman Sachs Downgrades Harmony Biosciences Holdings to Sell From Neutral, Cuts Price Target to $31 From $40	23-09-25	MT
Berenberg Initiates Coverage on Harmony Biosciences at Buy, $59 Price Target	23-09-07	MT
Raymond James Adjusts Price Target on Harmony Biosciences to $58 From $62, Maintains Outperform Rating	23-08-02	MT
Mizuho Securities Cuts Price Target on Harmony Biosciences to $54 From $60, Maintains Buy Rating	23-08-02	MT
Cantor Fitzgerald Adjusts Price Target on Harmony Biosciences Holdings to $75 From $71, Maintains Overweight Rating	23-05-03	MT
BofA Securities Initiates Coverage on Harmony Biosciences With Neutral Rating, $35 Price Target	23-04-20	MT
Goldman Sachs Adjusts Price Target on Harmony Biosciences Holdings to $43 From $49, Maintains Neutral Rating	23-02-22	MT
Needham Trims Price Target on Harmony Biosciences Holdings to $67 From $70, Keeps Buy Rating	23-02-22	MT
Mizuho Adjusts Price Target on Harmony Biosciences to $60 From $70, Reiterates Buy Rating	23-02-22	MT
Piper Sandler Adjusts Harmony Biosciences Holdings Price Target to $70 From $62, Maintains Overweight Rating	23-01-04	MT
Mizuho Adjusts Price Target on Harmony Biosciences Holdings to $70 From $60, Maintains Buy Rating	22-11-08	MT
Needham Adjusts Price Target on Harmony Biosciences Holdings to $65 From $60, Maintains Buy Rating	22-11-02	MT
Goldman Sachs Lowers Harmony Biosciences Holdings Price Target to $51 From $58, Maintains Neutral Rating	22-10-21	MT
Jefferies Upgrades Harmony Biosciences Holdings to Buy From Hold, Adjusts Price Target to $61 From $57	22-10-14	MT
Goldman Sachs Raises Price Target on Harmony Biosciences to $58 From $56, Maintains Neutral Rating	22-08-04	MT